Loading organizations...
§ Private Profile · Singapore, Central Region, Singapore
Pre-clinical biotechnology company developing AUTACs for targeted protein degradation in oncology, inflammation, and CNS disorders.
Based in Singapore, Automera is a pre-clinical biotechnology company that develops autophagy-targeting chimera small molecules to selectively degrade disease-causing proteins, mitochondria, viruses, and bacteria. The organization utilizes computational chemistry, artificial intelligence, and quantum molecular dynamics to design precise targeted therapeutics primarily focused on oncology, inflammation, and central nervous system disorders. Operating as an early-stage research and development venture, the firm aims to create proprietary drug candidates for eventual clinical trials, commercialization, or pharmaceutical partnerships. The enterprise emerged from stealth mode in September 2023 after securing $16 million in initial venture capital funding to advance its proprietary drug pipeline. This financing round was co-led by Accelerator Life Science Partners and ClavystBio, with additional equity participation from institutional investors EDBI and Xora Innovation. Automera was founded in 2023 by Michael Lazarou, Loong Wang, and Taiyang Zhang.
Automera has raised $16.0M across 1 funding round.
Automera has raised $16.0M in total across 1 funding round.
Automera has raised $16.0M in total across 1 funding round.
Automera's investors include Thong Le, Wen Qi Ho, EDBI, Xora Innovation.
Automera has raised $16.0M across 1 funding round. Most recently, it raised $16.0M Series A in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 27, 2023 | $16M Series A | Thong LE, WEN QI HO | EDBI, Xora Innovation | Announced |